Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS-553 in diabetic macular edema
NCT04187443Phase 1Recruiting
- Sponsor
- MingSight Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MS-553 in diabetic macular edema (DME) (3 arms), sponsored by MingSight Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events at 8 weeks. Started Jun 2020; status: recruiting.
02
Drugs
MS-553
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04187443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187443.